Clinical Trial Update: Sorafenib/Docetaxel Dose Escalation Trial [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial evaluating sorafenib in combination with docetaxel has completed, focusing on safety and dosing in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Nexavar (Sorafenib)
• Taxotere (docetaxel)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED